CD274 and neoplasm: However, in the real world, the actual clinical effect of pembrolizumab monotherapy in patients with low PD-L1 expression or posterior line therapy has not been explored in too many studies, mainly because these patients have a heavy tumor load themselves, and for these patients, the main purpose of treatment is to rapidly reduce the tumor volume, prevent excessive disease progression, and increase progression-free survival.